SS
NBIX icon

Sunbelt Securities’s Neurocrine Biosciences NBIX Stock Holding History

Sunbelt Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35K Hold
266
– – ﹤0.01% 1121
2025
Q4 		$37.7K Sell
266
-57
-18% -$8.26K ﹤0.01% 1073
2025
Q3 		$45.3K Buy
323
+31
+11% +$4.2K ﹤0.01% 1025
2025
Q2 		$39.9K Hold
292
– – ﹤0.01% 995
2025
Q1 		$32.3K Hold
292
– – ﹤0.01% 1001
2024
Q4 		$40K Hold
292
– – ﹤0.01% 992
2024
Q3 		$33.6K Hold
292
– – ﹤0.01% 1039
2024
Q2 		$40.2K Hold
292
– – ﹤0.01% 960
2024
Q1 		$40.3K Sell
292
-33
-10% -$4.51K ﹤0.01% 927
2023
Q4 		$42.8K Hold
325
– – 0.01% 846
2023
Q3 		$36.6K Buy
325
+83
+34% +$8.74K 0.01% 875
2023
Q2 		$22.8K Hold
242
– – ﹤0.01% 989
2023
Q1 		$24K Buy
+242
New +$25.2K ﹤0.01% 909
2020
Q2 		– Sell
-15,668
Closed -$1.53M – 351
2020
Q1 		$1.53M Buy
+15,668
New +$1.53M 0.07% 112

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sunbelt Securities's NBIX Position: Q1 2026 in Review

Sunbelt Securities held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 266 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

Sunbelt Securities first reported a position in NBIX in Q1 2020 and has held it in 14 quarters since. The position peaked at $1.53M in Q1 2020. 699 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Sunbelt Securities held 266 shares of Neurocrine Biosciences worth $35K as of Q1 2026.
  • Sunbelt Securities left its Neurocrine Biosciences share count unchanged in Q1 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #1121 holding.
  • Sunbelt Securities first reported a position in Neurocrine Biosciences in Q1 2020 and has held it in 14 quarters since.
  • Sunbelt Securities's Neurocrine Biosciences position peaked at $1.53M in Q1 2020.
  • 699 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.